Background:
Hyperthermic intraoperative intraperitoneal chemotherapy (hiic) has been recently proposed to treat peritoneal carcinomatosis arising from colon adenocarcinoma, which is usually regarded as a lethal clinical entity. the purpose of this study was to evaluate the clinical outcome of this combined treatment.
Methods:
A retrospective study of 46 patients treated for peritoneal carcinomatosis from colon adenocarcinoma was performed. thirty-four patients were treated with complete cytoreductive surgery immediately followed by intraoperative hiic with mitomycin c and cisplatin. the clinical outcome of these 34 patients was analyzed; the median follow-up period was 14.5 months.
Results:
No postoperative deaths were reported. the postoperative morbidity rate was 35%. no severe locoregional or systemic toxicity was observed. the 2-year overall survival was 31%, and the median survival time and the median time to local disease progression were 18 and 13 months, respectively. survival and local disease control in patients with well- and moderately differentiated colon adenocarcinoma were significantly better than in those with poorly differentiated tumors.
Conclusions:
Considering the dismal prognosis of this condition, hiic seems to achieve encouraging results in a selected group of patients affected with resectable peritoneal carcinomatosis arising from colon adenocarcinoma. these findings support the conduction of formal phase iii randomized trials.